Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H.

Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496.

PMID:
29997251
2.

Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment?

Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME.

Expert Rev Anti Infect Ther. 2018 May;16(5):411-422. doi: 10.1080/14787210.2018.1471355. Epub 2018 May 8.

PMID:
29722275
3.

Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.

Scott N, Hainsworth SW, Sacks-Davis R, Pedrana A, Doyle J, Wade A, Hellard M.

J Virus Erad. 2018 Apr 1;4(2):108-114.

4.

Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.

Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051.

5.

Achieving hepatitis C elimination in Europe - To treatment scale-up and beyond.

Hellard M, Scott N, Sacks-Davis R, Pedrana A.

J Hepatol. 2018 Mar;68(3):383-385. doi: 10.1016/j.jhep.2017.12.004. Epub 2017 Dec 9. No abstract available.

PMID:
29233629
6.

Pathways to the elimination of hepatitis C: prioritising access for all.

Pedrana AE, Sacks-Davis R, Doyle JS, Hellard ME.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1023-1026. doi: 10.1080/17512433.2017.1383894. No abstract available.

PMID:
28942660
7.

Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.

Bradshaw D, Raghwani J, Jacka B, Sacks-Davis R, Lamoury F, Down I, Prestage G, Applegate TL, Hellard M, Sasadeusz J, Dore GJ, Pybus OG, Matthews GV, Danta M.

PLoS One. 2016 Sep 1;11(9):e0162002. doi: 10.1371/journal.pone.0162002. eCollection 2016.

8.

Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks.

Hellard M, Sacks-Davis R, Doyle J.

J Epidemiol Community Health. 2016 Jun 24. pii: jech-2015-205454. doi: 10.1136/jech-2015-205454. [Epub ahead of print] No abstract available.

PMID:
27343304
9.

The role of living context in prescription opioid injection and the associated risk of hepatitis C infection.

Sacks-Davis R, Daniel M, Roy É, Kestens Y, Zang G, Ramos Y, Hellard M, Jutras Aswad D, Bruneau J.

Addiction. 2016 Nov;111(11):1985-1996. doi: 10.1111/add.13470. Epub 2016 Jul 21. No abstract available.

PMID:
27238912
10.

Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.

Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, Matthews G, Rice TM, Morris MD, McGovern BH, Kim AY, Bruneau J, Lloyd AR, Page K, Manns MP, Hellard ME, Dore GJ; InC3 Study Group.

J Viral Hepat. 2015 Dec;22(12):1020-32. doi: 10.1111/jvh.12429. Epub 2015 Jun 22.

11.

Hepatitis C transmission and treatment as prevention - The role of the injecting network.

Hellard M, McBryde E, Sacks Davis R, Rolls DA, Higgs P, Aitken C, Thompson A, Doyle J, Pattison P, Robins G.

Int J Drug Policy. 2015 Oct;26(10):958-62. doi: 10.1016/j.drugpo.2015.05.006. Epub 2015 May 21.

PMID:
26072105
12.

The use of social networking platforms for sexual health promotion: identifying key strategies for successful user engagement.

Veale HJ, Sacks-Davis R, Weaver ER, Pedrana AE, Stoové MA, Hellard ME.

BMC Public Health. 2015 Feb 6;15:85. doi: 10.1186/s12889-015-1396-z.

13.

Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, Spelman T, Bruneau J, Prins M, Kim AY, McGovern BH, Shoukry NH, Schinkel J, Allen TM, Morris M, Hajarizadeh B, Maher L, Lloyd AR, Page K, Hellard M; InC3 study group.

J Infect Dis. 2015 Nov 1;212(9):1407-19. doi: 10.1093/infdis/jiv220. Epub 2015 Apr 15.

14.

How "hidden" are unobserved networks among people who inject drugs?

Higgs P, Sacks-Davis R, Aitken C, Hellard M.

Am J Public Health. 2015 Jun;105(6):e3. doi: 10.2105/AJPH.2015.302667. Epub 2015 Apr 16. No abstract available.

15.

Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Dore GJ, Grebely J; InC3 Study Group.

PLoS One. 2015 Apr 2;10(4):e0122232. doi: 10.1371/journal.pone.0122232. eCollection 2015.

16.

Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.

Sacks-Davis R, McBryde E, Grebely J, Hellard M, Vickerman P.

J R Soc Interface. 2015 Mar 6;12(104):20141197. doi: 10.1098/rsif.2014.1197.

17.

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC3 Study Group.

J Viral Hepat. 2015 Sep;22(9):708-17. doi: 10.1111/jvh.12384. Epub 2015 Jan 8.

18.

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC(3)Study Group.

J Clin Virol. 2014 Nov;61(3):430-4. doi: 10.1016/j.jcv.2014.08.027. Epub 2014 Sep 8.

19.

The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.

Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, Aitken C, McBryde E.

Hepatology. 2014 Dec;60(6):1861-70. doi: 10.1002/hep.27403. Epub 2014 Oct 24.

PMID:
25163856
20.

Young people's comfort receiving sexual health information via social media and other sources.

Lim MS, Vella A, Sacks-Davis R, Hellard ME.

Int J STD AIDS. 2014 Dec;25(14):1003-8. doi: 10.1177/0956462414527264. Epub 2014 Mar 10.

PMID:
24616114
21.

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.

Flynn JK, Sacks-Davis R, Higgs P, Aitken C, Moneer S, Suppiah V, Tracy L, Ffrench R, Bowden S, Drummer H, George J, Bharadwaj M, Hellard M.

Hepat Mon. 2014 Jan 8;14(1):e14678. doi: 10.5812/hepatmon.14678. eCollection 2014 Jan.

22.

Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.

Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, Hutchinson SJ, Hellard ME.

Int J Drug Policy. 2014 Jan;25(1):179-82. doi: 10.1016/j.drugpo.2013.08.005. Epub 2013 Sep 8.

PMID:
24315504
23.

High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.

Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, Bharadwaj M, Nivarthi UK, Suppiah V, George J, Grebely J, Drummer HE, Hellard M.

PLoS One. 2013 Nov 7;8(11):e80216. doi: 10.1371/journal.pone.0080216. eCollection 2013.

24.

Hepatitis C transmission and treatment in contact networks of people who inject drugs.

Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, Robins G, Hellard M.

PLoS One. 2013 Nov 1;8(11):e78286. doi: 10.1371/journal.pone.0078286. eCollection 2013.

25.

The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection.

Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; InC3 Study Group.

Hepatology. 2014 Jan;59(1):109-20. doi: 10.1002/hep.26639. Epub 2013 Nov 22.

26.

Eradication of hepatitis C infection: the importance of targeting people who inject drugs.

Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E.

Hepatology. 2014 Feb;59(2):366-9. doi: 10.1002/hep.26623. Epub 2013 Dec 24. No abstract available.

27.

Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs.

Sacks-Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, Rolls D, Pattison P, Robins G, Grebely J, Barry A, Hellard M.

PLoS One. 2012;7(10):e47335. doi: 10.1371/journal.pone.0047335. Epub 2012 Oct 26.

28.

Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.

Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK.

Med J Aust. 2012 Jun 4;196(10):638-41.

PMID:
22676879
29.

Identifying newly acquired cases of hepatitis C using surveillance: a literature review.

Sacks-Davis R, VAN Gemert C, Bergeri I, Stoove M, Hellard M.

Epidemiol Infect. 2012 Nov;140(11):1925-34. Epub 2012 Jun 1. Review.

PMID:
22651915
30.

The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.

Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, Hellard M; International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3).

J Infect Dis. 2012 May 1;205(9):1342-50. doi: 10.1093/infdis/jis213. Epub 2012 Mar 29. Erratum in: J Infect Dis. 2012 Aug 15;206(4):624. InC Collaborative Group [corrected to International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3)].

31.

Modelling hepatitis C transmission over a social network of injecting drug users.

Rolls DA, Daraganova G, Sacks-Davis R, Hellard M, Jenkinson R, McBryde E, Pattison PE, Robins GL.

J Theor Biol. 2012 Mar 21;297:73-87. doi: 10.1016/j.jtbi.2011.12.008. Epub 2011 Dec 16.

PMID:
22185979
32.

Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.

Higgs P, Sacks-Davis R, Gold J, Hellard M.

Hepat Mon. 2011 Jul;11(7):513-8.

33.

Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review.

Sacks-Davis R, Horyniak D, Grebely J, Hellard M.

Int J Drug Policy. 2012 May;23(3):176-84. doi: 10.1016/j.drugpo.2011.08.002. Epub 2011 Oct 13. Review.

PMID:
22000602
34.

A systematic examination of the use of online social networking sites for sexual health promotion.

Gold J, Pedrana AE, Sacks-Davis R, Hellard ME, Chang S, Howard S, Keogh L, Hocking JS, Stoove MA.

BMC Public Health. 2011 Jul 21;11:583. doi: 10.1186/1471-2458-11-583. Review.

35.

The Australian national binge drinking campaign: campaign recognition among young people at a music festival who report risky drinking.

van Gemert C, Dietze P, Gold J, Sacks-Davis R, Stoové M, Vally H, Hellard M.

BMC Public Health. 2011 Jun 20;11:482. doi: 10.1186/1471-2458-11-482.

36.

Home-based chlamydia testing of young people attending a music festival--who will pee and post?

Sacks-Davis R, Gold J, Aitken CK, Hellard ME.

BMC Public Health. 2010 Jun 28;10:376. doi: 10.1186/1471-2458-10-376.

37.

Randomised controlled trial of paper, online and SMS diaries for collecting sexual behaviour information from young people.

Lim MS, Sacks-Davis R, Aitken CK, Hocking JS, Hellard ME.

J Epidemiol Community Health. 2010 Oct;64(10):885-9. doi: 10.1136/jech.2008.085316. Epub 2009 Sep 18.

PMID:
19767322
38.

Hepatitis C treatment for injection drug users: a review of the available evidence.

Hellard M, Sacks-Davis R, Gold J.

Clin Infect Dis. 2009 Aug 15;49(4):561-73. doi: 10.1086/600304. Review.

PMID:
19589081

Supplemental Content

Loading ...
Support Center